Oscar Huertas

SOM Innovation Biotech SA engages in the discovery and development of new indications for known drugs. Its pipeline consists of repositioned compounds for the treatment of amyloidosis, huntington's disease, hyperplasia, glioblastoma, and alzheimer's disease. The company was founded by Raul Insa Boronat and Ignasi Belda Reig on December 30, 2009 and is headquartered in Barcelona, Spain.

SOM Innovation Biotech SA engages in the discovery and development of new indications for known drugs. Its pipeline consists of repositioned compounds for the treatment of amyloidosis, huntington's disease, hyperplasia, glioblastoma, and alzheimer's disease. The company was founded by Raul Insa Boronat and Ignasi Belda Reig on December 30, 2009 and is headquartered in Barcelona, Spain.

SOM Innovation Biotech SA engages in the discovery and development of new indications for known drugs. Its pipeline consists of repositioned compounds for the treatment of amyloidosis, huntington's disease, hyperplasia, glioblastoma, and alzheimer's disease. The company was founded by Raul Insa Boronat and Ignasi Belda Reig on December 30, 2009 and is headquartered in Barcelona, Spain.

SOM Innovation Biotech SA engages in the discovery and development of new indications for known drugs. Its pipeline consists of repositioned compounds for the treatment of amyloidosis, huntington's disease, hyperplasia, glioblastoma, and alzheimer's disease. The company was founded by Raul Insa Boronat and Ignasi Belda Reig on December 30, 2009 and is headquartered in Barcelona, Spain.

SOM Innovation Biotech SA engages in the discovery and development of new indications for known drugs. Its pipeline consists of repositioned compounds for the treatment of amyloidosis, huntington's disease, hyperplasia, glioblastoma, and alzheimer's disease. The company was founded by Raul Insa Boronat and Ignasi Belda Reig on December 30, 2009 and is headquartered in Barcelona, Spain.